IRIS
LAPUCCI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.429
Totale 2.429
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.429
Totale 2.429
Salva come PNG Salva come JPEG
Città #
Genova 1.276
Genoa 741
Rapallo 383
Vado Ligure 19
Bordighera 10
Totale 2.429
Salva come PNG Salva come JPEG
Nome #
Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers 133
Different MRI patterns in MS worsening after stopping fingolimod 129
Osteopathic Manipulative Therapy and Multiple Sclerosis: A Proof-of-Concept Study 126
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 115
Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of “black holes” 104
How much do periventricular lesions assist in distinguishing migraine with aura from CIS? 101
Could arterial spin labelling perfusion imaging uncover the invisible in N-methyl-d-aspartate receptor encephalitis? 96
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 95
"Limbic encephalitis with acute onset and Hu antibodies treated with rituximab: Paraneoplastic or non-paraneoplastic disorder?" 94
Effects of aging on finger movements in multiple sclerosis 92
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 87
Two-way crossed cerebellar diaschisis in a clinically isolated syndrome suggestive of multiple sclerosis 77
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 76
123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies 75
Neuroimaging Findings in Mild Cognitive Impairment 66
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 65
A longitudinal clinical and MRI evaluation of the treatment with erenumab 62
Assessing upper limb function in Multiple Sclerosis by an engineered glove 59
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population 57
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 52
Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study 44
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 44
null 41
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 41
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 38
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 38
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 34
Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis 34
ADVANCED SUSCEPTIBILITY AND DIFFUSION WEIGHTED IMAGING IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS: FROM RESEARCH TO CLINICAL APPLICATIONS 34
In-vivo characterization of macro- and microstructural injury of the subventricular zone in relapsing-remitting and progressive multiple sclerosis 33
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis 30
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 28
Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature 27
A real-world study of alemtuzumab in a cohort of Italian patients 27
Clinical and radiological correlates of apathy in multiple sclerosis 25
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 25
Embracing resilience in multiple sclerosis: a new perspective from COVID-19 pandemic 25
Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma 21
Central vein sign and diffusion MRI differentiate microstructural features within white matter lesions of multiple sclerosis patients with comorbidities 20
The role of disconnection in explaining disability in multiple sclerosis 20
Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study 20
Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia 19
Improved detection of multiple sclerosis lesions with T2-prepared double inversion recovery at 3T 19
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 15
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis 14
Mapping tissue microstructure across the human brain on a clinical scanner with soma and neurite density image metrics 13
Vaccinations in patients with multiple sclerosis: a real-world, single-center experience 12
Sex differences in neuroimaging biomarkers in healthy subjects and dementia 10
null 8
The effect of Cladribine and Fingolimod treatments on retinal atrophy 7
A real-world study of Alemtuzumab in a cohort of Italian patients 7
Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study 6
Vaccinations in patients with multiple sclerosis: a real-world, single-center, experience 6
Coagulation activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis 4
Effect of SARS-CoV-2 mRNA vaccination in multiple sclerosis patients treated with disease modifying therapies 3
Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection 2
E200k familial creutzfeldt-jakob disease presenting with subacute multiple cranial neuropathy 2
Totale 2.557
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.852
article - articoli 11.255
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 416
Totale 23.523
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020586 31 11 18 44 55 96 77 61 63 68 50 12
2020/2021344 25 18 36 62 49 32 13 22 22 38 15 12
2021/2022339 21 4 12 28 21 30 12 72 27 43 19 50
2022/2023480 43 50 10 47 50 68 7 29 66 14 74 22
2023/2024628 24 42 18 76 35 83 122 37 30 19 36 106
2024/202585 85 0 0 0 0 0 0 0 0 0 0 0
Totale 2.557